PDCD1 and esophageal squamous cell carcinoma: Anti‐programmed death‐1 (anti‐PD‐1) antibodies combined with chemotherapy have been recommended as the standard‐of‐care for the first‐line treatment in advanced ESCC patients according to the results from multiple randomized phase 3 trials.11, 12